國藥現代(600420.SH):子公司現代哈森通過藥品GMP符合性檢查
格隆匯12月30日丨國藥現代(600420.SH)公佈,近日,公司控股子公司上海現代哈森(商丘)藥業有限公司(“現代哈森”)收到河南省藥品監督管理局《藥品GMP檢查結果吿知書》。
本次GMP符合性檢查為現代哈森原料藥VI車間在現有生產線基礎上新增鹽酸倍他司汀原料藥生產範圍,該車間上述認證項目是在原有廠房、設備情況下新增生產產品,無較大工程費用投入。
鹽酸倍他司汀屬於血管擴張藥,可用於腦動脈硬化、缺血性腦血管病,也用於高血壓病所致的直立性眩暈、耳鳴等症,以及由於腦供血不足引起的眩暈、頭暈等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.